REPL
Replimune Group, Inc.Company Information
- Company Name
- Replimune Group, Inc.
- CIK
- CIK0001737953
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- REPL: Nasdaq
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- REPL
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 216,585
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 94,358,603
- Shares outstanding
- 96,864,452
- Ownership
- 97.41%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.47%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 185 | 209 | 123 | 102 | 97 | 111 | 172 | 113 | 152 | 74 | 98 | 76 | ||||||
| Short Term Investments | 10 | 60 | 146 | 221 | 306 | 373 | 364 | 319 | 317 | 346 | 369 | 421 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 9 | 8 | 8 | 8 | 8 | 8 | 9 | 6 | 8 | 9 | 9 | ||||||
| Assets Current | 201 | 279 | 280 | 334 | 413 | 496 | 548 | 443 | 480 | 434 | 479 | 508 | ||||||
| Property Plant And Equipment Net | 12 | 13 | 14 | 15 | 15 | 14 | 14 | 13 | 11 | 10 | 9 | 8 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 3 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 0 | - | - | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | ||||||
| Finance Lease Right Of Use Asset | 32 | 32 | 33 | 34 | 34 | 35 | 35 | 36 | 37 | 37 | 38 | 38 | ||||||
| Assets | 252 | 332 | 334 | 389 | 470 | 551 | 604 | 498 | 535 | 488 | 533 | 562 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 7 | 6 | 6 | 15 | 12 | 7 | 8 | 1 | 3 | 4 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 30 | 48 | 40 | 42 | 40 | 46 | 37 | 31 | 31 | 34 | 31 | 32 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Current | 38 | 58 | 50 | 53 | 60 | 62 | 48 | 44 | 36 | 40 | 39 | 40 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Finance Lease Liability Noncurrent | 22 | 22 | 22 | 22 | 23 | 23 | 23 | 23 | 23 | 23 | 24 | 24 | ||||||
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 44 | 29 | ||||||
| Long Term Debt Noncurrent | 84 | 83 | 48 | 47 | 47 | 46 | 46 | 46 | 45 | 45 | - | - | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities | 147 | 166 | 123 | 126 | 133 | 135 | 121 | 117 | 109 | 113 | 111 | 97 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,432 | 1,423 | 1,394 | 1,377 | 1,368 | 1,359 | 1,351 | 1,186 | 1,177 | 1,071 | 1,063 | 1,055 | ||||||
| Retained Earnings Accumulated Deficit | -1,332 | -1,263 | -1,189 | -1,118 | -1,035 | -949 | -874 | -808 | -755 | -701 | -646 | -595 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 6 | 5 | 6 | 5 | 4 | 5 | 6 | 4 | 4 | 5 | 5 | 5 | ||||||
| Stockholders Equity | 106 | 166 | 211 | 263 | 337 | 416 | 482 | 381 | 426 | 375 | 422 | 465 | ||||||
| Liabilities And Stockholders Equity | 252 | 332 | 334 | 389 | 470 | 551 | 604 | 498 | 535 | 488 | 533 | 562 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 84 | 83 | 80 | 78 | 78 | 77 | 77 | 68 | 68 | 61 | 61 | 59 | ||||||
| Shares Outstanding | 84 | 83 | 80 | 78 | 78 | 77 | 77 | 68 | 68 | 61 | 61 | 59 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialReplimune Group, Inc. (REPL) — SEC Financial Statements & Analysis
Replimune Group, Inc. (REPL) is a biological products, (no diagnostic substances) company, incorporated in DE. Replimune Group, Inc. trades on Nasdaq as: REPL. Replimune Group, Inc. (REPL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Replimune Group, Inc. carries a market cap of $1.07B, a P/E ratio of -3.61x, a P/B ratio of 10.15x, an enterprise value of $972.25M, and an EV/EBITDA multiple of -3.30x. On profitability, it posts a Return on Equity (ROE) of -134.29%, a Return on Assets (ROA) of -82.28%, and a Return on Invested Capital (ROIC) of -203.10%. Per share, it reports EPS of $-3.07, diluted EPS of $-3.07, free cash flow per share of $-2.90, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 5.99% year-over-year and EPS growth of 0.14% year-over-year. On the balance sheet, it maintains a current ratio of 5.23x, a quick ratio of 5.09x, working capital of $162.40M, a debt-to-equity ratio of 1.39x, a debt ratio of 0.58, an interest coverage ratio of -37.68x, free cash flow of $-280.55M (TTM), and net debt of $-100.04M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.07B
- P/E TTM
- -3.61x
- EPS TTM
- $-3.07
- P/B TTM
- 10.15x
- ROE TTM
- -134.29%
- ROA TTM
- -82.28%
- Debt To Equity
- 1.39x
- Free Cash Flow TTM
- $-280.55M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Replimune Group, Inc. in?
Replimune Group, Inc. (REPL) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does REPL trade on?
Replimune Group, Inc. (REPL) trades on the Nasdaq.
Where is Replimune Group, Inc. incorporated?
Replimune Group, Inc. is incorporated in DE.
When was Replimune Group, Inc. (REPL)'s most recent SEC filing?
Replimune Group, Inc. (REPL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is REPL's market cap?
Replimune Group, Inc. (REPL) has a market capitalization of $1.07B as of 2026-06-30.
What is REPL's EPS (earnings per share)?
Replimune Group, Inc. (REPL)'s trailing twelve month EPS is $-3.07 as of 2026-06-30.
What is REPL's ROE (return on equity)?
Replimune Group, Inc. (REPL)'s trailing twelve month Return on Equity (ROE) is -134.29% as of 2026-06-30.
What is REPL's ROA (return on assets)?
Replimune Group, Inc. (REPL)'s trailing twelve month Return on Assets (ROA) is -82.28% as of 2026-06-30.
What is REPL's ROIC (return on invested capital)?
Replimune Group, Inc. (REPL)'s trailing twelve month Return on Invested Capital (ROIC) is -203.10% as of 2026-06-30.
What is REPL's EV/EBITDA?
Replimune Group, Inc. (REPL)'s trailing twelve month EV/EBITDA is -3.30x as of 2026-06-30.